Barinthus Biotherapeutics plc (BRNS)
Sep 9, 2026 - BRNS was delisted (reason: merged with CLYD)
0.7401
0.00 (0.00%)
Inactive · Last trade price on Sep 8, 2026
Barinthus Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
30.23M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 14.97M | 14.17M | 1,766.46% |
| Dec 31, 2023 | 802.00K | -43.90M | -98.21% |
| Dec 31, 2022 | 44.70M | 44.44M | 16,580.22% |
| Dec 31, 2021 | 268.00K | -4.55M | -94.44% |
| Dec 31, 2020 | 4.82M | -2.02M | -29.57% |
| Dec 31, 2019 | 6.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
BRNS News
- 4 weeks ago - Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics - GlobeNewsWire
- 7 weeks ago - Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 7 weeks ago - Barinthus Biotherapeutics Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Barinthus Biotherapeutics Earnings release: Q2 2026 - Filings
- 3 months ago - Barinthus Biotherapeutics Proxy statement: Proxy filing - Filings
- 4 months ago - Barinthus Biotherapeutics Proxy statement: Proxy filing - Filings
- 4 months ago - Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 4 months ago - Barinthus Biotherapeutics Earnings release: Q1 2026 - Filings